1. Home
  2. OCG vs ARTL Comparison

OCG vs ARTL Comparison

Compare OCG & ARTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Oriental Culture Holding LTD

OCG

Oriental Culture Holding LTD

HOLD

Current Price

$0.67

Market Cap

3.8M

ML Signal

HOLD

Logo Artelo Biosciences Inc.

ARTL

Artelo Biosciences Inc.

HOLD

Current Price

$1.20

Market Cap

3.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
OCG
ARTL
Founded
2018
2011
Country
Hong Kong
United States
Employees
N/A
N/A
Industry
Other Consumer Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.8M
3.5M
IPO Year
2019
N/A

Fundamental Metrics

Financial Performance
Metric
OCG
ARTL
Price
$0.67
$1.20
Analyst Decision
Buy
Analyst Count
0
3
Target Price
N/A
$30.00
AVG Volume (30 Days)
450.5K
27.8K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
7.63%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.01
$0.85
52 Week High
$19.29
$28.60

Technical Indicators

Market Signals
Indicator
OCG
ARTL
Relative Strength Index (RSI) 39.02 42.77
Support Level $0.04 $1.10
Resistance Level $4.24 $1.50
Average True Range (ATR) 0.10 0.13
MACD -0.02 0.00
Stochastic Oscillator 11.14 33.33

Price Performance

Historical Comparison
OCG
ARTL

About OCG Oriental Culture Holding LTD

Oriental Culture Holding Ltd is an online provider of collectibles and artwork e-commerce services. The company also offers online and offline integrated marketing, storage, and technical maintenance services to customers. The company operates through one segment, namely, e-commerce of artwork trading. It generates revenue through listing service fees, transaction fees, and other revenues collected from traders.

About ARTL Artelo Biosciences Inc.

Artelo Biosciences Inc is a United States-based development-stage biopharmaceutical company. It is engaged in the development of therapeutics that target lipid signaling pathways, including the endocannabinoid system, a family of receptors & neurotransmitters that form a biochemical communication network in the body. It is focused on discovering, licensing, developing, & commercializing treatments that control endocannabinoid systems. The company pursues technologies & programs that offer proprietary approaches to cannabinoid-based therapies, & those derived from the cannabis plant & synthetic cannabinoids, as well as new chemical entities & compounds. The firm's flagship program is designed to be a patent-protected cannabinoid drug combination treatment for a rare & orphan disease.

Share on Social Networks: